LB Pharmaceuticals

tenant

drug

Losartan

MeSH D019808

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

small molecule

Pre-approval / investigational in the US

Developed by Mclean Hospital

1 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

small molecule

Indications

Investigational (via trials)

Schizophrenia Cardiovascular Disease Bipolar Disorder Mental Disorders Schizophrenia Depressive Disorder, Major Major Depressive Disorder Serious Mental Illness Psychosis NOS Cardiovascular Diseases Bipolar Disorder Psychotic Disorders Schizoaffective Disorder

Trials

1

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

NCT02188121Phase 4Completed

KOLs & investigators

1

Dost Ongur, MD, PhD

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

Mclean Hospital

company

trial

Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients

PHASE4

trial

indication

indication

Cardiovascular Disease

indication

Bipolar Disorder

indication

Mental Disorders

indication

KOL

Dost Ongur, MD, PhD

KOL score —

person